Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

You are reading 1 of 2 free-access articles allowed for 30 days

RCSI scientists with partners make colorectal cancer drug discovery

By Mindo - 01st Jun 2018 | 35 views

The RCSI described the discovery as a “critical advance” in the global effort to move towards a more personalised treatment for colorectal cancer patients.

“This study has identified a potential biomarker that could be used by doctors in the future to distinguish between patients who will benefit from Avastin, and patients who will not respond,” said Professor Annette Byrne, Associate Professor at RCSI’s Department of Physiology and Medical Physics.

“Further research is ongoing to develop a laboratory test so that the biomarker can be applied in clinical daily practice.

“Our overall goal is to improve the standard-of-care for colorectal cancer and to make sure that patients only receive drugs that will work specifically in the setting of their own disease. This will reduce side-effects, treatment costs and improve patient outcomes.”

According to the RCSI by predicting the patients that would not benefit from Avastin, individuals could be spared the side-effects of this particular drug therapy, and are more likely to receive optimal treatment with a minimum of delay, while reducing cost of care.

The study, led by researchers at VU University Medical Centre Amsterdam (VUmc) and RCSI  is published in the Journal of Clinical Oncology.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read